Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From Guatemala

NCT01857752 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT01857752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01857752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From Guatemala
Lead sponsor
Stanford University
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2012
Completion date
June 30, 2015
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

retinoblastoma